Evidence-based support for phenotypic drug discovery in acute myeloid leukemia

Area of Science:

• Oncology
• Pharmacology
• Translational Medicine

Background:

• Cancer drug development faces high attrition rates from early clinical trials.
• Understanding factors predicting clinical success is crucial for improving drug development pipelines.
• Acute myeloid leukemia (AML) serves as a model for investigating drug development challenges.

Approach:

• A comprehensive meta-analysis of 2918 clinical studies involving 466 unique drugs tested in AML.
• Examination of pre-clinical drug development strategies and their correlation with clinical outcomes.
• Comparative analysis of different pre-clinical drug discovery methods.

Key Points:

• Phenotypic drug discovery demonstrated a stronger correlation with positive clinical outcomes compared to other pre-clinical methods.
• Identified shared pre-clinical characteristics that distinguish successful from unsuccessful drugs in AML.
• The study highlights the need for evidence-based recommendations in pre-clinical drug selection.

Conclusions:

• Phenotypic drug discovery is recommended as a preferred pre-clinical approach for cancer therapeutics.
• Findings from AML drug development may inform and improve discovery platforms for other cancer types.
• Optimizing pre-clinical strategies can enhance the efficiency and success rate of clinical cancer drug development.